IM Cannabis Corp. IMCC

IM Cannabis Corp. closed a US$1.31 million registered direct offering, selling 655,000 common shares at US$2.00 to accredited investors. Gross proceeds will fund working capital and general corporate purposes, including pursuing additional opportunities. The offering used IMCC’s Form F-3 shelf registration, with shares issued via a prospectus supplement. Invest-Pro – SHUKAI HON LTD., a related party and director Eli Zamir’s affiliate, subscribed for 164,585 shares for US$329,170, creating a related-party transaction under MI 61-101. The company relied on exemptions due to financial hardship after board and independent-director determinations that it was in serious financial difficulty and that the terms were reasonable; Zamir abstained from voting. A material change report will be filed. IMCC operates in Israel and Germany; a pending sale of I.M.C. Holdings Ltd. would leave Israeli operations with IMCC while German operations would be held indirectly by the purchaser via Adjupharm GmbH. Small financing improves liquidity but governance concerns from a related-party transaction temper investor sentiment.

IM Cannabis Corp. (Nasdaq: IMCC) says it has regained Nasdaq's minimum $1 bid price requirement after its shares closed at $1.00 or higher for 18 consecutive trading days (Aug. 27–Sept. 22, 2026). Nasdaq notified IMC that the deficiency is resolved. The company notes pending transactions announced on August 17, 2026; upon completion, it expects to retain its Israeli medical cannabis operations while its German operations will be sold via Adjupharm GmbH. IMC operates in Israel, sourcing and distributing cannabis to medical patients, and runs medical cannabis retail pharmacies and online platforms in Israel. The announcement confirms continued Nasdaq listing and outlines a planned strategic repositioning in Europe as part of its broader corporate actions. Regaining Nasdaq minimum bid price compliance reduces delisting risk and the planned sale of German operations signals a major strategic shift affecting asset mix and growth prospects.

IM Cannabis Corp. signed a non-binding LOI to acquire 51% of Space Defense Innovations LLC (SDI), a Polish entity that distributes BlueBird Aero Systems' tactical UAS in Europe and, through its subsidiary BlueAero Group Sp. z o.o., is set to become a European manufacturer with exclusivity in Poland. Terms provide a mix of IMCC common shares (capped so SDI holders own no more than 19.99% of IMCC) and/or pre-funded warrants, plus a 24‑month seller loan at 9% interest with 100% warrant coverage exercisable at a 25% premium to the closing price. IMCC would obtain a five-year option to acquire the remaining SDI shares, the right to appoint a majority of SDI's board, and an on‑demand line of credit up to EUR 2.3 million convertible into SDI shares, subject to a US$5 million minimum valuation. Definitive agreements expected within 60 days; closing depends on due diligence and approvals; no guarantee. Potentially significant strategic diversification into European UAS/defense tech if the deal closes, but is non-binding and subject to due diligence and approvals.

IM Cannabis Corp. priced a registered direct offering of approximately 655,000 common shares at US$2.00 per share, raising about US$1.31 million before expenses. Closing is expected around September 24, 2026, subject to usual conditions. Proceeds will be used for working capital and general corporate purposes, including evaluating potential additional opportunities. The offering is conducted under the Company’s Form F-3 shelf registration. Some investors may be related parties, and the company intends to rely on exemptions from MI 61-101 for related-party transactions on the basis of financial hardship. Separately, following August 17, 2026 announcements, the German operations are expected to be sold while Israeli operations are retained. The press release also includes a standard forward-looking statements disclaimer and notes regulatory and market risks. Small, liquidity-focused financing with potential strategic implications from the German sale, yielding a moderate overall impact on the company’s trajectory.

IM Cannabis Corp. intends to execute a 30:1 share consolidation to meet Nasdaq minimum bid price rules and maintain its listing. 30:1 consolidation supports Nasdaq compliance but represents a routine defensive step unlikely to shift core operations or long-term trajectory.

IM Cannabis enters agreement to sell IMC Holdings and European-focused assets. Divestiture of IMC Holdings plus European assets constitutes major strategic shift likely to alter operations and investor outlook.

IM Cannabis Corp. enters letter of intent to sell its European activities and expects to reduce debt by CAD$10.5 million. Divestiture of European operations cuts debt by CAD$10.5 million and materially improves balance sheet.

IM Cannabis Corp. announced its first quarter 2026 financial results. Quarterly earnings reports affect financial performance and investor sentiment but are routine updates.

IM Cannabis Corp. received a Nasdaq notification for non-compliance with the minimum bid price requirement, as its stock closed below $1 for 30 consecutive business days. Nasdaq deficiency notice poses delisting risk, significantly threatening market access and investor sentiment.

IM Cannabis Corp. (IMCC) reported 2025 results with C$54.7 million revenue, over 134% growth in Germany, and positive operating cash flow. Strong revenue growth exceeding 134% in Germany combined with positive operating cash flow positions IMCC for enhanced market performance and investor confidence.

IM Cannabis Corp. (IMC) announces strategic entry into cyber drone interception and satellite intelligence markets through a non-binding agreement to acquire 51% of Blackaxe Technologies. Non-binding agreement for 51% stake in unrelated cyber-drone and satellite firm signals major diversification from cannabis core, potentially reshaping trajectory and investor sentiment.

IM Cannabis Corp. (IMCC) has successfully raised US$2,171,660.40 through note purchase agreements. This funding is part of the company's strategy to enhance its financial position and support its growth initiatives in the cannabis market. The funding raised through note purchase agreements may moderately influence IMCC's financial performance and growth strategy.

IM Cannabis Corp. has appointed Mr. Alon Dayan to its Board of Directors, enhancing its leadership team as it continues to navigate the evolving cannabis market. Dayan brings extensive experience in corporate governance and strategic development, which is expected to support the company's growth initiatives and operational strategies. The appointment of a new board member may influence strategic direction and governance but is not expected to drastically change the company's overall trajectory.

IM Cannabis Corp. (IMCC) is considering entering the U.S. market following an executive order by President Trump aimed at enhancing research into medical marijuana and cannabidiol. The company sees potential opportunities for growth and expansion in the U.S. cannabis sector as regulatory changes may facilitate increased access and acceptance of cannabis products. IMCC's exploration of this market aligns with broader trends in the industry, reflecting a strategic move to capitalize on evolving legal landscapes. The executive order could significantly alter the regulatory environment, opening up new market opportunities for IMCC.

IM Cannabis Corp. has appointed Asi Levi as its new Chief Financial Officer, effective immediately. Levi brings over 20 years of experience in finance and management, having held various leadership roles in public companies. His expertise is expected to enhance the company's financial strategy and operations as IM Cannabis continues to expand in the cannabis market. The appointment of a new CFO can moderately influence financial performance and strategic direction.

IM Cannabis Corp. (IMCC) reported its financial results for the third quarter of 2025, highlighting key metrics such as revenue growth and operational developments. The company continues to expand its market presence and enhance product offerings, reflecting a strategic focus on increasing shareholder value. Management provided insights into future initiatives aimed at sustaining growth and navigating the evolving cannabis landscape. Significant revenue growth and strategic initiatives indicate a strong potential for altering the company's trajectory.

IM Cannabis Corp.'s market capitalization has plummeted to $7.4 million, resulting in significant financial losses for insiders. The decline reflects ongoing challenges within the cannabis industry, raising concerns about the company's future viability and investor confidence. The drastic drop in market cap indicates significant challenges that could alter the company's trajectory and investor sentiment.

IM Cannabis Corp. (IMCC) has signed a non-binding term sheet to acquire a 60% stake in an innovative quantum computing bio data company for up to $54 million. This strategic move aims to enhance IMCC's technological capabilities and expand its market presence in the cannabis sector. Acquiring a stake in a quantum computing bio data company could significantly enhance IMCC's technological edge and market positioning.

IM Cannabis Corp. (IMCC) has announced changes to its board of directors and is strategically seeking additional business opportunities. These moves are part of the company's efforts to enhance its operational framework and explore new avenues for growth in the cannabis sector. Board changes and the pursuit of new business opportunities may moderately influence the company's strategic direction and market positioning.

IM Cannabis Corp. has regained compliance with Nasdaq's stockholders' equity listing requirement, following a successful restructuring of its financial position. The company reported an increase in its stockholders' equity, which allowed it to meet the necessary criteria for continued listing on the exchange. This development is expected to enhance investor confidence and stabilize the company's market presence. Regaining compliance with Nasdaq's requirements positively influences investor sentiment and market stability, but the overall impact on long-term performance remains limited.

IM Cannabis Corp. announced amendments to its warrants and filed a Form F-3 resale registration statement. These changes are part of the company's ongoing efforts to optimize its capital structure and enhance liquidity. The amendments are expected to provide more flexibility in managing its financial resources. Warrant amendments and the registration statement may influence financial performance and market sentiment but are not expected to fundamentally alter the company's trajectory.

IM Cannabis Corp. (IMCC) reported its financial results for the second quarter of 2025, highlighting key metrics such as revenue growth and operational developments. The company continues to expand its market presence and enhance product offerings, reflecting a strategic focus on growth in the cannabis sector. Management provided insights into future initiatives aimed at improving profitability and market share, indicating a positive outlook despite industry challenges. Significant revenue growth and strategic initiatives are likely to impact future performance and investor sentiment.

IM Cannabis Corp. (IMCC) has successfully closed a private placement, generating gross proceeds of approximately US$4.1 million. The funds raised are intended to support the company's growth initiatives and operational strategies. This financing is part of IMCC's ongoing efforts to strengthen its financial position and expand its market presence. The private placement provides necessary capital that may enhance operational capabilities and market positioning.

IM Cannabis Corp. (IMCC) has filed a shelf registration statement on Form F-3 with the U.S. Securities and Exchange Commission. This filing allows the company to offer and sell securities in the future, providing flexibility for capital raising. The registration statement is part of IMCC's strategy to enhance its financial position and support growth initiatives. The filing of a shelf registration statement may provide IM Cannabis with necessary capital for future growth, impacting its financial performance moderately.

IM Cannabis Corp. (IMCC) has signed a loan agreement to enhance its financial position and appointed Oz Adler to its Board of Directors, aiming to strengthen governance and strategic direction. The loan agreement and board appointment may moderately influence the company's financial performance and governance structure.

IM Cannabis Corp. (IMCC) has announced several corporate updates, including the completion of its acquisition of a cannabis company, which is expected to enhance its market position. The company also reported on its operational performance and strategic initiatives aimed at expanding its product offerings and improving financial results. Additionally, IMCC highlighted its commitment to regulatory compliance and sustainability in its operations. The acquisition and strategic initiatives are likely to significantly impact IMCC's market position and financial performance.

IM Cannabis Corp. has applied for a voluntary delisting of its common shares from the Canadian Securities Exchange (CSE), effective June 2, 2025. The company believes that maintaining a dual listing incurs unnecessary costs and that trading volume on the CSE no longer justifies these expenses. The delisting will not affect its NASDAQ listing, where shares will continue to trade under the symbol 'IMCC'. IM Cannabis expresses gratitude to the CSE for its support and aims to centralize its marketplace on NASDAQ to enhance liquidity and shareholder value. Delisting from the CSE may streamline operations and reduce costs, impacting financial performance moderately.

IM Cannabis Corp. announced the results of its annual general and special meeting held on May 23, 2025, where shareholders approved all resolutions, including the election of directors and the completion of the Focus Transaction. The Company closed the Focus Transaction on May 26, 2025, settling a debt of approximately C$313,970.17 through the issuance of 128,818 Common Shares. Additionally, the Company completed a Secured Debenture Offering, raising C$2,301,174.70, with participation from insiders Oren Shuster and Rafael Gabay. The article also includes details on the exercise of Pre-Funded Warrants by Mr. Shuster and early warning disclosures related to the acquisition of securities by the Acquirors. The completion of significant transactions and insider participation indicates a strategic shift that could significantly impact the company's future performance.

IM Cannabis Corp (IMCC) reported Q1 2025 revenue of 12.5 million CAD, a 4% increase from Q1 2024, and achieved a net profit of 0.2 million CAD, reversing a loss of 6 million CAD from the previous year. Gross margin improved by 87%, while adjusted EBITDA turned positive at 0.6 million CAD. German revenue surged by 569%, but Israeli revenue fell by 56%, partly due to the cancellation of an organin bill. Operating expenses decreased by 56% to 3.3 million CAD. Cash balance rose to 1.4 million CAD, and total assets increased by 15%. However, total liabilities also grew by 16%. The company is navigating challenges between markets and needs additional capital for future operations. Significant revenue growth in Germany and a return to profitability indicate a major strategic shift for the company.

IM Cannabis Corp. (IMC) reported its Q1 2025 financial results, achieving a net profit of $175K and a 94% increase in gross profit to $3.4M compared to Q1 2024. Revenue rose 4% to $12.5M, driven by growth in Germany, despite a decline in Israel. Operating expenses decreased by 56% to $3.3M, and Non-IFRS Adjusted EBITDA improved by 129% to $0.6M. The company plans to complete a private placement of secured convertible debentures for up to C$2.5M. Management highlighted the results as a turning point for sustained growth. A conference call is scheduled for further discussion. Achieving net profitability and significant gross margin improvement indicates a major strategic shift that could enhance investor sentiment and market performance.